Answers are grounded in this paper and cite their sources.
Gingival hyperplasia (GH) is defined as an increase in size or overgrowth of the gingiva, the most common cause being drug-induced gingival overgrowth (DIGO). Among drugs, the common culprits are antiepileptics such as phenytoin, immunosuppressive drugs such as cyclosporine, and calcium channel blockers (CCBs) such as amlodipine and nifedipine. Factors such as genetic susceptibility, pro-inflammatory state, and poor oral hygiene accentuate the probability of developing DIGO. The condition is managed by identifying the causative drug, stopping or substituting it with another drug of the same or different class, along with nonsurgical measures such as scaling and root planing or by surgical procedures. Among the CCBs, there have been frequent reports of DIGO associated with nifedipine and amlodipine and substituting them with newer agents like benidipine has actually been shown to improve the condition without compromising blood pressure control. However, literature also suggests that GH can also be caused by benidipine itself, although rarely. Here, we are reporting a rare case of benidipine-induced GH in a 36-year-old female, which is one among the first few such cases to be reported to the best of our knowledge.
No takes yet. Share an insight, caveat, or question.
Agrawal et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: